Zevra Therapeutics Faces Investor Probe Following Regulatory Setback
A 24% single-day collapse in Zevra Therapeutics shares has triggered a formal investigation into potential securities law violations. The stock plummeted on July 24, 2026, after European regulators delivered a negative opinion on the company's experimental drug arimoclomol, marking the firm’s steepest percentage decline in five years.














.jpg)












